These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35143051)

  • 21. From the margins to mainstream: How providers of autologous 'stem cell treatments' legitimise their practice in Australia.
    MacGregor C; Petersen A; Munsie M
    Health (London); 2021 Jan; 25(1):51-68. PubMed ID: 31081381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unproven stem cell therapies: is it my right to try?
    Riva L; Campanozzi L; Vitali M; Ricci G; Tambone V
    Ann Ist Super Sanita; 2019; 55(2):179-185. PubMed ID: 31264641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders.
    Matthews KR; Iltis AS
    BMC Med Ethics; 2015 Nov; 16(1):75. PubMed ID: 26537611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tracking the rise of stem cell tourism.
    Ryan KA; Sanders AN; Wang DD; Levine AD
    Regen Med; 2010 Jan; 5(1):27-33. PubMed ID: 20017692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What's missing? Discussing stem cell translational research in educational information on stem cell "tourism".
    Master Z; Zarzeczny A; Rachul C; Caulfield T
    J Law Med Ethics; 2013; 41(1):254-68. PubMed ID: 23581669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing persuasive health education for patients seeking unproven stem cell interventions.
    Kawam O; Zhu X; Eton DT; Martin-Lillie C; Finney Rutten LJ; Shapiro S; Tilburt JC; Master Z
    Stem Cell Reports; 2023 Aug; 18(8):1549-1554. PubMed ID: 37557072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?
    Fang WH; Vangsness CT
    Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory loophole enables unproven autologous cell therapies to thrive in Australia.
    Munsie M; Pera M
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():34-8. PubMed ID: 25457959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The "Growing" Reality of the Neurological Complications of Global "Stem Cell Tourism".
    Julian K; Yuhasz N; Hollingsworth E; Imitola J
    Semin Neurol; 2018 Apr; 38(2):176-181. PubMed ID: 29791943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer "cell therapy" clinics.
    Hinkle JW; Mahmoudzadeh R; Kuriyan AE
    Stem Cell Res Ther; 2021 Oct; 12(1):538. PubMed ID: 34635174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teaching non-FDA approved nonprescription products: Educating students about potential risks and liability.
    Van Dusen V; Pray WS
    Curr Pharm Teach Learn; 2019 Jul; 11(7):655-657. PubMed ID: 31227086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International stem cell tourism and the need for effective regulation. Part I: Stem cell tourism in Russia and India: clinical research, innovative treatment, or unproven hype?
    Cohen CB; Cohen PJ
    Kennedy Inst Ethics J; 2010 Mar; 20(1):27-49. PubMed ID: 20506693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
    Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
    Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
    [No Abstract]   [Full Text] [Related]  

  • 37. In Response To: Professor Cassileth's manuscript on "Alternative and Complementary Cancer Treatments," Featured in The Oncologist 1996;1:173-179.
    Quah TC
    Oncologist; 1996; 1(5):324-325. PubMed ID: 10388010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The European Court of Human Rights' ruling on unproven stem cell therapies: a missed opportunity?
    Rial-Sebbag E; Blasimme A
    Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):39-43. PubMed ID: 25457960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Academic Physician Specialists' Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapies-A Qualitative Analysis.
    Smith C; Crowley A; Munsie M; Behfar A; DeMartino ES; Staff NP; Shapiro SA; Master Z
    Mayo Clin Proc; 2021 Dec; 96(12):3086-3096. PubMed ID: 34454715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.